Description
BSE/ICCL announces the settlement calendar for Aurobindo Pharma Limited buyback acquisition window running from April 23 to April 29, 2026, with settlement date of May 7, 2026.
Summary
ICCL (Indian Clearing Corporation Ltd.) has published the settlement calendar for the Offer to Buy – Acquisition Window (Buyback) for Aurobindo Pharma Limited. The buyback bidding window is open from April 23, 2026 to April 29, 2026, under Settlement No. 2026042, with the final settlement date set for May 7, 2026.
Key Points
- Buyback acquisition window runs from April 23, 2026 to April 29, 2026 (Settlement No. 2026042)
- Demat shares must be delivered exclusively through the Early Pay-in of Shares mechanism available on both CDSL and NSDL depositories
- Members/Custodians must use Market Type “(Buyback)” and Settlement No. 2026042 in the depository system
- CDSL & NSDL early pay-in securities will be earmarked/blocked in client accounts under the requisite market type and settlement number
- Members and Custodians are NOT required to upload any EPN file
- Members should refer to the
MBRSTD_OTB_CM_mmm_SettNofile for client-wise Stamp Duty charges
Regulatory Changes
No new regulatory changes introduced. Members/Custodians are directed to refer to Notice No. 20200528-32 dated May 28, 2020, regarding settlement as per the Revised Guidelines of Mechanism for Acquisition of Shares through Stock Exchange.
Compliance Requirements
- Participants must ensure early pay-in of securities is reflected in BSE/ICCL systems before the prescribed timelines for accepting/confirming bids on the BSE OTB platform
- Early pay-in must be completed sufficiently in advance of the closure of the BSE OTB Bidding window (for members placing bids) and the Confirmation window (for Custodians confirming bids)
- Use correct Market Type “(Buyback)” and Settlement No. 2026042 in depository instructions
Important Dates
| Event | Date |
|---|---|
| Bid Start Date | April 23, 2026 |
| Bid End Date | April 29, 2026 |
| Obligation Download | May 6, 2026 |
| Settlement Date | May 7, 2026 |
Impact Assessment
This circular is operationally relevant to stock exchange members and custodians participating in the Aurobindo Pharma buyback. Participants must coordinate early pay-in of shares through CDSL or NSDL ahead of the OTB platform deadlines to ensure bids are accepted. The buyback window is short (7 days), making timely action critical. No broad market impact is expected beyond participants directly involved in the Aurobindo Pharma buyback process. For clarifications, members may contact the ICCL Help Desk at 022-69158590/45720490/45720690 or iccl.helpdesk@icclindia.com.
Impact Justification
Routine buyback settlement schedule announcement affecting members and custodians participating in Aurobindo Pharma's acquisition window; operationally significant for participants but limited broader market impact.